Aug 12, 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Mar 25, 2020
TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
Feb 25, 2020
IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer
Dec 10, 2019
EMD Serono and the pan-Canadian Pharmaceutical Alliance Complete Negotiations for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis
Nov 20, 2019
Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations
Sep 11, 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Jun 20, 2019
Massachusetts-based Business Sectors of Merck KGaA, Darmstadt, Germany Named 'Best Places to Work' by Boston Business Journal
Jun 03, 2019
Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations
Mar 14, 2019
Merck KGaA, Darmstadt, Germany, Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology
Dec 20, 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Dec 06, 2018
Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
Jun 03, 2018
Merck KGaA, Darmstadt, Germany Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018
Mar 27, 2018
Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan
Mar 07, 2018
Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis
Feb 16, 2018
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing
Nov 17, 2017
Merck KGaA, Darmstadt, Germany's Massachusetts-based Business Sectors Named 'Top Place to Work' by The Boston Globe
Nov 07, 2017
Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer
Nov 04, 2017
Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
Oct 27, 2017
Merck KGaA Darmstadt, Germany Announces Recipients of EUR1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017
Oct 09, 2017
Interview Opportunity: Curiosity Cube(TM) Arrives in Burlington